Olink Holding AB (OLK)
23.24
+0.08
(+0.37%)
USD |
NASDAQ |
May 07, 16:00
23.24
0.00 (0.00%)
After-Hours: 20:00
Olink Cash from Financing (TTM): 92.50M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 92.50M |
September 30, 2023 | 92.49M |
June 30, 2023 | 92.63M |
March 31, 2023 | 92.49M |
December 31, 2022 | -2.884M |
September 30, 2022 | -3.012M |
June 30, 2022 | -2.872M |
Date | Value |
---|---|
March 31, 2022 | -3.319M |
December 31, 2021 | 179.06M |
September 30, 2021 | 184.92M |
June 30, 2021 | 185.00M |
March 31, 2021 | 198.82M |
December 31, 2020 | 25.60M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-3.319M
Minimum
Mar 2022
198.82M
Maximum
Mar 2021
87.03M
Average
92.49M
Median
Mar 2023
Cash from Financing (TTM) Benchmarks
Thermo Fisher Scientific Inc | -2.85B |
Abliva AB | 0.0391M |
Karolinska Development AB | -0.0782M |
Calliditas Therapeutics AB | -- |
Oncopeptides AB | 11.82M |